Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Clin Cancer Res. 2018 Mar 12;24(13):3108–3118. doi: 10.1158/1078-0432.CCR-17-2961

Figure 1.

Figure 1.

Oncoprint of alterations identified in tumor samples from patients with EGFR-mutant lung cancer pre-treatment (green) and after treatment (pink) with an EGFR TKI. The frequency is noted on the right. The type of genetic alteration (missense, inframe, truncated, amplification, deletion, fusion) is described in the legend, and the comutations present in ≥5% of cases were included in the figure. HER2 and MET amplification were included due to their relevance in acquired resistance.